BUDESONIDE MODULATES B- AND T-CELL IMMUNITY IN PEYER'S PATCHES: IMPLICATIONS FOR IgA NEPHROPATHY

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 

 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

  Back
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/46eaa4d9e28d2620154673eb0444428e.pdf
BUDESONIDE MODULATES B- AND T-CELL IMMUNITY IN PEYER'S PATCHES: IMPLICATIONS FOR IgA NEPHROPATHY

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Roza
Ghotbi
Roza Ghotbi roza.ghotbi@calliditas.com Calliditas Therapeutics AB Medical Affairs Stockholm Sweden *
Jens Kristensen jens.kristensen@calliditas.com Calliditas Therapeutics AB Clinical Development Stockholm Sweden -
Krassimir Mitchev krassimir.mitchev@calliditas.com Calliditas Therapeutics AB Clinical Development Stockholm Sweden -
Johan Häggblad johanhaggblad@gmail.com Calliditas Therapeutics AB Clinical Development Stockholm Sweden -